Key facts
- This page summarizes Peter Greenleaf's Form 4 filing for ANTARES PHARMA, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2021, 18:22.
Peter Greenleaf - 10 Jun 2021 Form 4 Insider Report for ANTARES PHARMA, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 10 Jun 2021
- Net transaction value
- +$112,498
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2021, 18:22:12 UTC
- Prior SEC filing
- 12 May 2021
- Next SEC filing
- 10 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa M. Kallebo as attorney-in-fact for Peter Greenleaf
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter Greenleaf filed Form 4 for ANTARES PHARMA, INC. on 14 Jun 2021.
Change
- Previous filing in this sequence was filed on 12 May 2021.
- Current net transaction value: +$112,498.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATRS
transaction
Common Stock
Award
- Transaction value
- $112,498
- Shares
- +25,452
- Change %
- +47%
- Price
- $4.42
- Shares after
- 79,645
- Date
- 10 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATRS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +48,542
- Change %
- Price
- $0.000000
- Shares after
- 48,542
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 48,542
- Exercise price
- $4.42
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date.
Footnote F2
Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan.
Footnote F3
The options vest and become exercisable one year from the grant date.